Delving into the Latest Updates on HS-10390 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

AT1/ETA antagonist(Hansoh)

+ [1]

Target

AT1R x ETA

Action

antagonists

Mechanism

AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), ETA antagonists(Endothelin receptor type A antagonists)

Therapeutic Areas

Immune System DiseasesUrogenital Diseases

Active Indication

Glomerulonephritis, IGAGlomerulosclerosis, Focal Segmental

Inactive Indication-

Originator Organization

Changzhou Humon Pharmaceutical Co., Ltd.

Shanghai Hansoh Biomedical Co. Ltd.

Active Organization

Changzhou Humon Pharmaceutical Co., Ltd.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

主要研究目的：在健康受试者中评价标准餐对HS-10390药代动力学的影响。次要研究目的：在空腹和标准餐后状态下，评价健康受试者单次口服HS-10390片后的安全性和耐受性。探索性研究目的：可能对健康受试者空腹状态单次口服HS-10390片后尿液和粪便中的 HS-10390进行浓度定量分析，以及对血样、尿样、粪便中 HS-10390代谢产物进行鉴定或特定代谢产物定量分析。

[Translation]

Primary study objective: To evaluate the effect of a standard meal on the pharmacokinetics of HS-10390 in healthy subjects. Secondary study objective: To evaluate the safety and tolerability of a single oral dose of HS-10390 tablets in healthy subjects in the fasting and standard meal state. Exploratory study objective: To quantitatively analyze the concentration of HS-10390 in urine and feces after a single oral dose of HS-10390 tablets in healthy subjects in the fasting state, and to identify HS-10390 metabolites in blood samples, urine samples, and feces or quantitatively analyze specific metabolites.

Start Date24 Oct 2024

Sponsor / Collaborator

Shanghai Hansoh Biomedical Co. Ltd.

[+2]

NCT05942625

/ RecruitingPhase 1

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Studyto Evaluate the Safety, Tolerability and Pharmacokinetics of HS-10390 in Healthy Subjects

The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.

Start Date23 May 2023

Sponsor / Collaborator

Shanghai Hansoh Biomedical Co. Ltd.

100 Clinical Results associated with HS-10390

Login to view more data

100 Translational Medicine associated with HS-10390

Login to view more data

100 Patents (Medical) associated with HS-10390

Login to view more data

100 Deals associated with HS-10390

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glomerulonephritis, IGA	Phase 2	China	Changzhou Humon Pharmaceutical Co., Ltd.	08 Oct 2024
Glomerulonephritis, IGA	Phase 2	China	Jiangsu Hansoh Pharmaceutical Co., Ltd.	08 Oct 2024
Glomerulosclerosis, Focal Segmental	Phase 1	China	Jiangsu Hansoh Pharmaceutical Co., Ltd.	18 May 2023
Glomerulosclerosis, Focal Segmental	Phase 1	China	Changzhou Humon Pharmaceutical Co., Ltd.	18 May 2023